Co-Founder and Chief Inspiration Officer (CIO)
Bryn Pharma's Co-Founder and Chief Inspiration Officer, Michelle Lobel, who has severe nut allergies, is the motivating force behind the Company and its drive to deliver a revolutionary product that addresses the needs of patients, doctors and caregivers. She is also the mother of two children who have severe nut allergies. Her search led her to create Bryn Pharma, a company driven to deliver a better alternative to epinephrine auto-injectors.
Prior to founding Bryn Pharma, Mrs. Lobel was a Vice President at IDEAL Fastener Corporation. When she began working at IDEAL, the firm was a North American manufacturer facing significant transformation challenges due to offshoring of production by the company’s customer base. Under her direct leadership, the firm initiated and grew to three company owned facilities in China and opened three sales and marketing offices to serve the offshore manufacturing capacity. During this process, Mrs. Lobel spent a full year negotiating and implementing a joint venture with a Chinese Manufacturer, a task with significant cross cultural and operational challenges. Mrs. Lobel’s experience at IDEAL has given her significant experience operating within unstructured entrepreneurial environments and in relentlessly pursuing solutions in a proactive fashion.
Michelle is extremely active in community leadership. She serves on the Board of Directors of the Food Allergy Fund, an organization dedicated to funding food allergy research focused on the underlying causes of food allergies and improved treatments for people with food allergies. Additionally, she volunteers at her children's various schools.
Michelle earned a B.A. in Economics from New York University.
Co-Founder and President
Steven Hartman spent over 25 years as a private equity investor. When his neighbor, Michelle, approached him with the various problems with epinephrine auto-injectors and how the allergy community was at risk, he immediately recognized that there was an opportunity to find A Better Way to deliver the epinephrine medication. Steven’s background and experience executing complex business transactions was the perfect complement to Michelle’s vision and since then they have worked tirelessly to bring Bryn Pharma from an idea to a reality.
Prior to founding Bryn Pharma, Mr. Hartman was a Partner, Co-Chief Operating Ofﬁcer, Chief Compliance Ofﬁcer and General Counsel of a large middle market private equity ﬁrm. Mr. Hartman had various roles including (i) participating as a voting member on all investment committees, (ii) responsible for all legal aspects of the private equity ﬁrm and its portfolio companies, (iii) responsible for all ﬁrm and portfolio company corporate governance. Mr. Hartman headed a team of investment professionals responsible for the negotiations of all investment activities from initial investment through investment realization and was responsible for creating complex legal, ﬁnancial and tax structuring for all of investment activities. Steven was responsible for all domestic and foreign compliance matters for the ﬁrm and its afﬁliates.
Steven earned a BS from UC Berkeley and JD/MBA from UCLA.
David Dworaczyk, PhD
Chief Executive Officer (CEO)
David, like Michelle, suffers from a life-threatening allergy, in his case bee stings. When he listened to her concerns about her twins, he knew first hand that her vision was right on target. Now, David is working tirelessly to create A Better Way for people at risk for anaphylaxis.
Dr. Dworaczyk has over 35 years of experience in the pharmaceutical, biotechnology, molecular diagnostic, medical device and CRO industry where he has held senior level positions in R&D, Global Operations, Business Development (L&A/M&A), Clinical Development, Strategic Planning, Project Management, Commercial Operations and healthcare analytics. Prior to joining Bryn Pharma, he directed the Life and Health Sciences Strategic Development effort at Oracle. He has also served as (i) COO for Comprehensive Clinical Development, (ii) Sr. Vice President, General Manager & COO at Generation Health/MetaDiagnostic, a start-up focused on molecular diagnostics, genomics and personalized medicine, (iii) was COO for The Moffitt Cancer Center/M2Gen (for-profit subsidiary) and (iv) Sr. VP at Quintiles.
Dr. Dworaczyk's experience is broad and he has had global responsibilities including leading operational functions across multiple business units, genomics/biomarkers, translational research, patient targeted drug development, gene based trial matching, translational research, precision/personalized medicine, healthcare analytics/informatics, population health as well as the integration and effective use of Real World Data/Evidence and “Big/Complex” data.
David earned a B.S and M.S in Molecular Biology from the State University of New York at Buffalo and a PhD in Leadership and Administration from the University of Delaware.
Chief Commercial Officer (CCO)
Like Michelle and David, Stephen is also allergic to a range of insects and must carry an auto-injector. As Chief Commercial Officer, Stephen is excited to help bring A Better Way of treating anaphylaxis to the millions of people suffering from life-threatening allergies.
Mr. Beckman is an executive and biotech leader with over 30 years of strategic commercialization, product launch and operational experience. Mr. Beckman is a strategic and innovative leader with a reputation for driving growth, productivity and transformation. His career history is packed with successes in guiding organizations to exceed commercial and operational objectives through broad cross-functional expertise in sales, marketing, product management, business development, partnership management and people leadership. With uniquely balanced experience in generic and brand pharmaceuticals from start-up to Big Pharma, Mr. Beckman has demonstrated repeated success developing and commercializing innovative products and solutions.
Prior to joining Mylan, Mr. Beckman served in a range of executive roles including (i) President & General Manager (Pharmaxis), (ii) VP of Global Marketing, Nycomed-Takeda (Altana Pharma), (iii) Sr. Worldwide Director, Cardio/Pulmonary Marketing (GSK), and (iv) Licensing/New Products Marketing Director AstraZeneca (Astra Merck Corporation).
Stephen actively participates in the life sciences community through a number of industry boards, committees and lecturing which has included the University of Pennsylvania (Wharton) Executive MBA – annual guest lecturer on business strategy and human capital, Adjunct lecturer at St. Joseph’s University Pharmaceutical Executive MBA, Committee member Genesyn IP Ventures in association with Temple University School of Medicine and health system and is also a professional photographer who donates services to multiple non-profit organizations to support their ongoing missions.
Stephen earned a B.S. in Business and Advertising from Syracuse University.
Chief Financial Officer (CFO)
Dale was excited to join a company focused on treatment options for the anaphylactic community. His firsthand experience with anaphylaxis, through his son’s severe nut allergy, reinforced for him the opportunity to positively impact the lives of millions of allergy sufferers. He is fully committed to creating a better solution for children.
Mr. Sander has served as Chief Financial Officer of six life science and business service companies. He has provided financial, operational and investor relations leadership to enable the commercialization of products and services on six continents, including three biotech companies he led from the pre-commercialization phase through the first product approval and market launch. Mr. Sander has transitioned entities from start-up to multi-billion-dollar global operations with 60,000 employees, including M&A integration, rapid commercial growth, global expansion, ERP implementation, and IPOs. He has driven strategic and business planning initiatives to maximize value from his companies’ services and products, and instituted dashboard and other reporting to provide real-time feedback of key drivers of customer, country, vertical global profitability. In addition to finance, Mr. Sander has led key operational and strategic areas of his organizations including strategic planning, corporate development, M&A, manufacturing, IT, legal, human resources, and facilities.
Prior to joining Bryn Pharma, Mr. Sander served as CFO of AVITA Medical, a regenerative medicine company with products marketed in the United States, Europe and Asia. He also served as SVP of Finance and Legal at Sutherland Global Services, a multi-billion-dollar business services company. Mr. Sander started his career with Ernst and Young as a Senior Manager in the San Diego office and National Emerging Businesses practice.
Dale has a B.S. Degree in Business from San Diego State University. He is a licensed certified public accountant.